Abstract
Immunoscintigraphy employing radiolabeled monoclonal antibodies (MoAbs) specific for certain selected tumor-associated antigens (TAAs) is becoming increasingly accepted as a routine diagnostic procedure, particularly for staging patients with cancer. In fact, even though the diagnostic potentials of immunoscintigraphy have been explored for diverse applications including cardiovascular diseases (for the detection of thrombi or of damaged myocardial cells), oncology is certainly the field where clinical validation of this new imaging method has been most extensive [for a brief overview on the clinical usefulness of immunoscintigraphy and on some pharmacokinetic aspects concerning this new diagnostic procedure, see Mariani and Strober, 1990]. It is now widely acknowledged that tumor immunoscintigraphy is of great value in terms of both specificity (close to 100%) and sensitivity (about 75–80% on the average). In addition, one of the major advantages of this procedure has been shown to be the ability of detecting distant tumor lesions in about one-third of patients who are apparently “tumor-free” as classified by other, noninvasive diagnostic techniques; therefore, for some specific forms of cancer, immunoscintigraphy may be considered as a mandatory diagnostic procedure for correctly staging and monitoring patients, complementary to other techniques already well established in the clinical routine [Mariani et al., 1989].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Buraggi G.L., 1985. Radioimmunodetection of cancer. J. Nucl. Med. Allied Sci. 29: 261.
Eger R.R., Covell D.G., Carrasquillo J.A., Abrams P.G., Foon K.A., Reynolds J.C., Schroff R.W., Morgan A.C., Larson S.M., Weinstein J.N.,. 1987. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res. 47: 3328.
Gobuty A.H., Kim E.E., Weiner R.E., 1985. Radiolabeled monoclonal antibodies: radiochemical pharmacoldnetic and clinical challenges. J. Nucl. Med. 26: 546.
Goodwin D.A., 1987. Pharmacokinetics and antibodies. J. Nucl. Med. 28: 1358.
Griffin T.W., Bokhari F., Collins J., Stochl M., Bernier M., Gionet M., Siebecker D., Wetheimer M., Giroves E.S., Grenfield L., Houston L.L., Doherty P.W., Wilson J., 1989. A preliminary pharmacokinetic study of 111In-labeled 260F9 anti-(breast cancer) antibody in patients. Cancer Immunol. Immunother. 29: 43.
Halpern S.E., Haindl W., Beauregard J., Hagan P., Clutter M., Amox D., Merchant B., Unger M., Mongovi C., Bartholomew R., Jue R., Carlo D., Dillman R., 1988. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. Radiology 168: 529.
Hayes D.F., Zalutsky M.R., Kaplan W., Noska M., Thor A., Colcher D., Kufe D.W., 1986. Pharmacoldnetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. Cancer Res. 46: 3157.
Hnatowich D.J., Gionet M., Rusckowski M., Siebecker D.A., Roche J., Shealy D., Mattis J.A., Wilson J., McGann J., Hunter R.E., Griffin T., Doherty P.W., 1987. Pharmacokinetics of 111In-labeled OC-125 antibody in cancer patients compared with the 19–9 antibody. Cancer Res. 47: 6111.
Kohler G., Milstein C., 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495.
Koizumi K., DeNardo G.L., DeNardo S.J., Hays M.T., Hines H.H., Scheibe P.O., Peng J.-S., Macey D.J., Tonami N., Hisada K., 1986. Multicompartmental analysis of the Idnetics of radioiodinated monoclonal antibody in patients with cancer. J. Nucl. Med. 27: 1243.
Larson S.M., Carrasquillo J.A., Reynolds J.C., 1984. Radioimmunodetection and radioimmunotherapy. Cancer Invest. 2: 363.
Mariani G.,. 1987. A protocol for screening tumour radioimmunoscintigraphy agents. In: “Lectures and Symposia, 14th International Cancer Congress, vol. 6: Epidemiology, Prevention, Diagnosis.” Lapis K. and Eckardt S., eds.), page 329. Akademiai Kiadb, Budapest.
Mariani G., Ferrante L., Rescigno A., 1986. Kinetic modeling for the analysis of digital images from tissue distribution studies of tumor radioimmunoscintigraphy agents. In: “Radioaktive Isotope in Klinik und Forschung, 17th (II).” ( Höfer R. and Bergmann H., eds.), page 741. Verlag H. Egerman, Wien.
Mariani G., Mazzuca N., Molea N., Bianchi R., Donato L., 1985. Kinetic distribution studies in vivo of radioiodinated monoclonal preparations as a screening procedure for tumour immunoscintigraphy agents. In: “Immunoscintigraphy.” ( Donato L. and Britton K., eds.), page 83. Gordon & Breach, New York and London.
Mariani G., Rosa C., Donato L.,. 1989. Comparison of the diagnostic sensitivity of tumor radioimmunoscintigraphy by means of an anti-CEA monoclonal antibody with other noninvasive diagnostic techniques. In: “Nuclear Medicine. Trends and Possibilities in Nuclear Medicine.” ( Schmidt H.A.E. and Buraggi G.L., eds.), page 527. Schattauer Verlag, Stuttgart.
Mariani G., Strober W., 1990 Immunoglobulin metabolism. In: “F c Receptors and the Action of Antibodies.” ( Metzeger H., ed.), page 94. American Society for Microbiology, Washington, D.C.
Marquardt D.W., 1963. An algorithm for least squares estimation of nonlinear parameters. SIAM J. 11: 431.
Murray J.L., Lamki L.M., Shanken L.J., Blake M.E., Plager C.E., Benjamin R.S., Schweighardt S., Unger M.W., Rosenblum M.G., 1988. Immunospecific saturable clearance mechanisms for Indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans. Cancer Res. 48: 4417.
Rescigno A., Bushe H., Brill A.B., Rusckowski M., Griffin T.W., Hnatowich D.J., 1990. Pharmacokinetic modeling of radiolabeled antibody distribution in man. Am. J. Physiol. Imaging 5: 141.
Rescigno A., Gurpide E., 1973. Estimation of average times of residence, recycle, and interconversion of blood-borne compounds using tracer methods. J. Clin. Endocrinol. Metab. 36: 263.
Rescigno A., Lambrecht R.M., Duncan C.C., 1983. Mathematical methods in the formulation of pharmacokinetic models. In: “Tracer Kinetics and Physiologic Imaging.” ( Lambrecht R.M. and Rescigno A., eds.), page 59. Springer Verlag, Berlin.
Rosenblum M.G., Murray J.L., Haynie T.P., Glenn H.J., Jahns M.F., Benjamin R.S., Frincke J.M., Carlo D.J., Hersh E.M., 1985. Pharmacokinetics of 111Inlabeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res. 45: 2382.
Rosenblum M.G., Murray J.L., Lamki L., David G., Carlo D.J., 1987. Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies. Cancer Chemother. Pharmacol. 20: 41.
Sheiner L.B., 1981. Extended least square fit (ELSFIT). Technical Report, Division of Clinical Pharmacology, University of California.
Working Group Meeting, 1986. Radioimmunoimaging - Report. Hybridoma 5: 166.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Mariani, G., Ferrante, L., Rescigno, A. (1991). Pitfalls in Pharmacokinetic Modeling of Monoclonal Antibody Biodistribution in Man. In: Rescigno, A., Thakur, A.K. (eds) New Trends in Pharmacokinetics. NATO ASI Series, vol 221. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8053-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8053-5_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8055-9
Online ISBN: 978-1-4684-8053-5
eBook Packages: Springer Book Archive